Literature DB >> 16052630

Long-term treatment with anti-alpha 4 integrin antibodies aggravates colitis in G alpha i2-deficient mice.

Malin Bjursten1, Paul W Bland, Roger Willén, Elisabeth Hultgren Hörnquist.   

Abstract

Targeted deletion of the heterotrimeric G protein, Galphai2, in mice induces lethal colitis closely resembling ulcerative colitis. In chronic colitis, migration of circulating leukocytes into the intestinal mucosa is partially dependent on alpha4 integrins. In previous studies, short-term administration of anti-alpha4 integrin antibodies has been shown to attenuate intestinal inflammation, and here we elucidate the effect of long-term administration of anti-alpha4 integrin antibodies on colitis in Galphai2(-/- )mice. Long-term blockade of alpha4 integrin significantly increased the severity of colitis in Galphai2(-/-) mice. The inflammation was confined to the colon, associated with increased cancer in situ, destruction of crypt architecture, and increased production of IL-1beta, TNF-alpha and IFN-gamma. Blockade of alpha4 integrin reduced the recruitment of activated T cells to the small intestine. In strong contrast, there were significantly higher numbers of activated T cells in the colonic lamina propria and epithelium, most probably due to in situ proliferation. Furthermore, treatment with alpha4 integrin antibodies induced decreased levels of total IgA and IgG in sera, whereas total IgM levels were unchanged. These new findings may have implications in the understanding of the progression of chronic intestinal inflammation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16052630     DOI: 10.1002/eji.200526022

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

Review 1.  Lessons for clinical trials from natalizumab in multiple sclerosis.

Authors:  Abhijit Chaudhuri
Journal:  BMJ       Date:  2006-02-18

Review 2.  Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there.

Authors:  Christopher C Denucci; Jason S Mitchell; Yoji Shimizu
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

3.  T cell-associated α4β7 but not α4β1 integrin is required for the induction and perpetuation of chronic colitis.

Authors:  E Kurmaeva; J D Lord; S Zhang; J R Bao; C G Kevil; M B Grisham; D V Ostanin
Journal:  Mucosal Immunol       Date:  2014-04-09       Impact factor: 7.313

4.  Regulatory B cells in autoimmune diseases and mucosal immune homeostasis.

Authors:  Xiaoxiao Li; Jonathan Braun; Bo Wei
Journal:  Autoimmunity       Date:  2010-08-11       Impact factor: 2.815

Review 5.  Gut-associated lymphoid tissue, T cell trafficking, and chronic intestinal inflammation.

Authors:  Iurii Koboziev; Fridrik Karlsson; Matthew B Grisham
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

6.  Psoriasis during natalizumab treatment for multiple sclerosis.

Authors:  Jorge Millán-Pascual; Laura Turpín-Fenoll; Pablo Del Saz-Saucedo; Ignacio Rueda-Medina; Santiago Navarro-Muñoz
Journal:  J Neurol       Date:  2012-10-25       Impact factor: 4.849

Review 7.  Role of beta7 integrins in intestinal lymphocyte homing and retention.

Authors:  G Gorfu; J Rivera-Nieves; K Ley
Journal:  Curr Mol Med       Date:  2009-09       Impact factor: 2.222

8.  Alterations in myeloid dendritic cell innate immune responses in the Galphai2-deficient mouse model of colitis.

Authors:  J A Peña; L Thompson-Snipes; P R Calkins; N Tatevian; M Puppi; M J Finegold
Journal:  Inflamm Bowel Dis       Date:  2009-02       Impact factor: 5.325

Review 9.  Inflammatory bowel disease: review from the aspect of genetics.

Authors:  Shunji Ishihara; M M Aziz; Takafumi Yuki; Hideaki Kazumori; Yoshikazu Kinoshita
Journal:  J Gastroenterol       Date:  2009       Impact factor: 7.527

10.  Deoxycholate-induced colitis is markedly attenuated in Nos2 knockout mice in association with modulation of gene expression profiles.

Authors:  Harris Bernstein; Hana Holubec; Carol Bernstein; Natalia A Ignatenko; Eugene Gerner; Katerina Dvorak; David Besselsen; Karen Ann Blohm-Mangone; Jose Padilla-Torres; Barbora Dvorakova; Harinder Garewal; Claire M Payne
Journal:  Dig Dis Sci       Date:  2007-03       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.